Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment

Abstract

Objective: To assess cardiometabolic biomarkers in patients with psoriasis before and after etanercept treatment.

Methods: Patients with moderate-to-severe plaque psoriasis were randomized to etanercept 50 mg once or twice weekly, double-blinded. Cardiometabolic biomarkers were assessed at baseline and after 12 weeks of treatment (n = 273).

Results: At baseline, 42% of patients had metabolic syndrome. Etanercept was not associated with any clinically relevant adverse effects on cardiometabolic biomarkers. In the once-weekly subgroup, significant mean percentage changes from baseline (p < 0.05) were observed for the quantitative insulin-sensitivity check index (QUICKI; −2.2%), apolipoprotein (Apo) A1 (3.2%), Apo B:Apo A1 ratio (−3.5%), leptin (8.6%) and high-sensitivity C-reactive protein (hsCRP) (−65.5%); and in the twice-weekly subgroup for plasma insulin (15.9%), QUICKI (−2.7%), high-density lipoprotein cholesterol (HDL-C; 2.9%), apolipoprotein (Apo) A1 (2.8%), Apo B:Apo A1 (−4.6%) and hsCRP (−74.4%).

Conclusion: Metabolic syndrome was common in these patients with moderate-to-severe psoriasis. Etanercept treatment may provide some potentially favorable modulation of insulin sensitivity, HDL-C, Apo A1 and Apo B:Apo A1 ratio.

• cardiovascular risk
• comorbidities
• etanercept
• metabolic syndrome
• psoriasis
• treatment

Acknowledgements

The authors thank all patients who participated in the study as well as the investigators and medical staff of all participating centers. In addition to the authors Lluís Puig and Robert Strohal, the PRISTINE trial investigators include: Peter Altmeyer, Bochum, Germany; Mario Amaya-Guerra, Nuevo León, Mexico; Matthias Augustin, Hamburg, Germany; Hugo Cabrera, Buenos Aires, Argentina; Petra Cetkovska, Plzen-Bory, Czech Republic; Edgardo Chouela, Buenos Aires, Argentina; Jozef De Weert, Gent, Belgium; Stefan Duban, Jihlava, Czech Republic; Dagmar Galatikova, Bruntal, Czech Republic; Ricardo Galimberti, Buenos Aires, Argentina; Pierre-Dominique Ghislain, Brussels, Belgium; Minerva Gomez, Nuevo León, Mexico; Zsuzsanna Karolyi, Miskolc, Hungary; Sarolta Karpati, Budapest, Hungary; Andreas Katsambas, Athens, Greece; Lajos Kemeny, Szeged, Hungary; Joo-Heung Lee, Gangnam-gu, Korea; Woan Lee, Taipei, Taiwan; Ulrich Mrowietz, Kiel, Germany; Nopadon Noppakun, Bangkok, Thailand; Ketty Peris, L’Aquila, Italy; Natta Rajatanavin, Bangkok, Thailand; Eva Remenyik, Debrecen, Hungary; Johannes Ring, Muenchen, Germany; Thomas Rosenbach, Osnabrueck, Germany; Michael Sticherling, Erlangen, Germany; Diamant Thaçi, Frankfurt, Germany; Tsen-Fang Tsai, Taipei, Taiwan; Guadalupe Villanueva, Jalisco, Mexico; and Jai II Youn, Seoul, Korea.

Notes

*Trial registration: ClinicalTrials.gov identifier NCT0066305